Proteomics International Laboratories Ltd (ASX:PIQ) presented its Chair's Address and Company Presentation at the 2026 Annual General Meeting on 20 November 2026, disclosing details of a Share Purchase Plan seeking to raise up to $5 million, a national distribution agreement with Healius, and the commercial availability of two diagnostic tests across Australia.
Key Points
- A Share Purchase Plan announced on 2 November seeks to raise up to $5 million before costs, with eligible shareholders able to apply for up to $30,000 of shares at 10 cents per share, scheduled to close on 25 November 2026.
- Each new share will carry one free attaching option exercisable at 15 cents, expiring two years from issue, subject to shareholder approval at the AGM.
- The Healius distribution agreement, signed in July, provides national collection network access for Proteomics International's tests without requiring the company to build its own pathology collection network.
- Promarker D and Promarker Eso are now commercially available across Australia, with Promarker Endo progressing towards launch.
- Assuming the full $5 million is raised, the funding package is expected to support operations to October 2027 based on company forecasts, not factoring for any Promarker revenue.
Share Purchase Plan Terms and Funding Outlook
The Share Purchase Plan, announced on 2 November, seeks to raise up to $5 million before costs. Eligible shareholders may apply for up to $30,000 of shares at 10 cents per share. Subject to shareholder approval, each new share will carry one free attaching option exercisable at 15 cents and expiring two years from issue, to be offered under a separate prospectus. The SPP is scheduled to close on 25 November 2026, unless varied under its terms. Assuming the full $5 million is raised, the funding package, including reported September cash and the R&D tax incentive, is expected to support operations to October 2027 based on company forecasts, and not factoring for any Promarker revenue.
Healius Agreement and Commercial Strategy
The company disclosed that a distribution agreement with Healius was signed in July, combining Healius' established collection network with Proteomics International's tests, specialist laboratory capability and clinical reporting to provide national access. The company said it adopted a distributor-led approach following a strategic and operational review, discontinuing the direct-to-consumer model and restructuring the organisation. The filing states the Healius agreement is also intended to serve future products as well as current ones. Funds raised through the SPP are intended to support Australian adoption, the planned Promarker Endo introduction, reimbursement work, laboratory operations, and US market readiness.
Leadership Changes and Founder Retirement
The filing disclosed that David Morris joined as Chief Executive Officer and Managing Director in January, bringing healthcare and medical technology experience. Morris led a strategic and operational review that resulted in changes to the company's commercial approach and organisational structure. The filing also disclosed that Dr Richard Lipscombe, the company's founder, retired from his executive and Board roles during the year after 25 years of leadership. The Chair's Address acknowledged Dr Lipscombe's contribution in building the company from a small laboratory to its current state as a diagnostics business.




Please wait processing your request...